Advances in Targeting B-Cell Maturation Antigen (BCMA) for Non-Invasive Imaging and Therapy in Multiple Myeloma
Recent advancements in the field of nuclear medicine have highlighted the significance of B-Cell Maturation Antigen (BCMA) as a pivotal target for the diagnosis and treatment of Multiple Myeloma (MM). In a groundbreaking study published in the European Journal of Nuclear Medicine and Molecular Imaging, a collaborative effort by the molecular imaging team at the First Affiliated Hospital of Jinan University and the Chinese Academy of Medical Sciences has demonstrated the efficacy of the radiolabeled antibody [89Zr]Zr-DFO-BCMAh230430 in non-invasive PET imaging of MM. This research represents a significant step forward in the development of specific immuno-PET probes targeting BCMA, which is highly expressed in malignant plasma cells.